{
    "nctId": "NCT02338167",
    "briefTitle": "Praegnant Breast Cancer: Early/Advanced/Metastatic",
    "officialTitle": "Prospective Academic Translational Research Network for the Optimization of the Oncological Health Care Quality in the Adjuvant and Advanced/Metastatic Setting: Health Care Research, Pharmacogenomics, Biomarkers, Health Economics",
    "overallStatus": "RECRUITING",
    "conditions": "Advanced/Metastatic Breast Cancer, Breast Cancer (Early Breast Cancer)",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 13500,
    "primaryOutcomeMeasure": "MBC (Metastatic Breast Cancer): Discovery of biomarkers, which predict progression free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria for the early breast cancer setting:\n\n* Adult breast cancer patients (age \u226518 years)\n* Patients with breast cancer and no evidence of distant metastases with a diagnosis not longer than 91 days before study entry\n* Patients, who are able and willing to sign the informed consent form\n\nInclusion Criteria for the advanced/metastatic setting:\n\n* Adult women aged \u226518 years\n* Patients with the diagnosis of invasive breast cancer (in German: Mammakarzinom, as op-posed to \"non-invasive\"= ductales Carcinoma in situ; irrespective of status of BC, e.g. TNM, re-ceptor status etc.) and\n* Patients, who are willing and able to sign the informed consent form\n* Patients with metastatic or locally advanced, inoperable disease proven by clinical measures (i.e. standard imaging)\n\nExclusion Criteria:\n\n* Patients who did not sign the informed consent form\n* Patients, who are not eligible for observation due to non-availability and/or severe comor-bidities as evaluated by the treating physician",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}